Aamir Sohail
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Aamir Sohail has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Imran Ullah
Division of Applied Life Science (BK21 Four), Gyeongsang National University, Jinju 52828, Gyeongnam Province, Republic of Korea
2 shared publications Aleena Altaf
Department of Biochemistry , Faculty of Biological Sciences , Quaid-i-Azam University , Islamabad , Pakistan , qau.edu.pk
1 shared publicationAmany I. Almars
Department of Medical Laboratory Sciences, Faculty of Applied Medical Science, King Abdulaziz University, Jeddah 21589, Saudi Arabia
1 shared publication- Atif Ali Khan Khalil
Department of Biotechnology, Yeungnam University, Gyeongsan 38541, Gyeongbuk, Republic of Korea
1 shared publication Hailah M. Almohaimeed
Department of Basic Science, College of Medicine, Princess Nourah Bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi Arabia
1 shared publication- Hajra Fayyaz
Department of Biochemistry, Faculty of Biological Sciences, Quaid-i-Azam University, Islamabad, Pakistan
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in BioMed Research International
- Vol. 2026 (1) , 8905392
Juglone Attenuates CCl₄‐Induced Hepatic Injury in Mice With Associated Modulation of Oxidative Stress and Inflammasome‐Related mRNA Expression
Carbon tetrachloride–induced liver injury is a well‐established model of toxic hepatitis, characterized by marked oxidative and inflammatory damage. It remains a relevant experimental system because broadly effective therapeutic options are still limited. Juglone, a natural naphthoquinone derived from Reynoutria japonica , has demonstrated antioxidant and anti‐inflammatory potential. However, mouse evidence combining standard liver injury measures with stress‐ and cell‐death gene profiling remains limited. Building on juglone studies in injury and fibrosis, we tested juglone in a CCl 4 model. Male C57BL/6 mice were assigned to normal, vehicle, CCl₄, silymarin (200 mg/kg), and juglone (8 mg/kg) groups, and CCl₄ (in corn oil) was administered intraperitoneally. Endpoints included body weight, serum liver enzymes and lipid profile, H&E histology, and RT‐qPCR panels for inflammatory, pyroptosis‐associated, ER stress and autophagy‐linked, apoptotic, oxidative‐stress, and profibrotic transcripts. CCl₄ exposure was associated with weight loss, enzyme elevation, dyslipidemia, and architectural disruption, whereas juglone treatment was associated with improved biochemical indices and histology alongside coordinated downregulation of inflammatory/pyroptosis‐related transcripts (including Il-1β , Il-6 , Nlrp3 , and Gsdmd ) and moderation of ER stress/autophagy and apoptosis‐linked transcripts, with downregulation of profibrotic transcripts ( Acta2 , Mmp2 , and Tgfβ1 ). In this mouse CCl₄ model, juglone treatment was associated with reduced serum and tissue injury signatures together with changes in stress and inflammation‐linked transcriptional programs. Because the molecular findings are primarily based on RT‐qPCR, these results are best interpreted as gene‐level associations compatible with modulation of oxidative stress, inflammasome‐ and pyroptosis‐related mRNA expression, ER stress responses, apoptosis‐linked transcripts, and remodeling‐associated transcripts, rather than as confirmed pathway inhibition or established antifibrotic activity. These data support juglone as a hepatoprotective candidate and identify protein‐level and functional validation as important next steps.
- 1 January 2026
- Published by Wiley in BioMed Research International
- Vol. 2026 (1) , 8905392
Open AccessJuglone Attenuates CCl₄‐Induced Hepatic Injury in Mice With Associated Modulation of Oxidative Stress and Inflammasome‐Related mRNA Expression
Carbon tetrachloride–induced liver injury is a well‐established model of toxic hepatitis, characterized by marked oxidative and inflammatory damage. It remains a relevant experimental system because broadly effective therapeutic options are still limited. Juglone, a natural naphthoquinone derived from Reynoutria japonica , has demonstrated antioxidant and anti‐inflammatory potential. However, mouse evidence combining standard liver injury measures with stress‐ and cell‐death gene profiling remains limited. Building on juglone studies in injury and fibrosis, we tested juglone in a CCl 4 model. Male C57BL/6 mice were assigned to normal, vehicle, CCl₄, silymarin (200 mg/kg), and juglone (8 mg/kg) groups, and CCl₄ (in corn oil) was administered intraperitoneally. Endpoints included body weight, serum liver enzymes and lipid profile, H&E histology, and RT‐qPCR panels for inflammatory, pyroptosis‐associated, ER stress and autophagy‐linked, apoptotic, oxidative‐stress, and profibrotic transcripts. CCl₄ exposure was associated with weight loss, enzyme elevation, dyslipidemia, and architectural disruption, whereas juglone treatment was associated with improved biochemical indices and histology alongside coordinated downregulation of inflammatory/pyroptosis‐related transcripts (including Il-1β , Il-6 , Nlrp3 , and Gsdmd ) and moderation of ER stress/autophagy and apoptosis‐linked transcripts, with downregulation of profibrotic transcripts ( Acta2 , Mmp2 , and Tgfβ1 ). In this mouse CCl₄ model, juglone treatment was associated with reduced serum and tissue injury signatures together with changes in stress and inflammation‐linked transcriptional programs. Because the molecular findings are primarily based on RT‐qPCR, these results are best interpreted as gene‐level associations compatible with modulation of oxidative stress, inflammasome‐ and pyroptosis‐related mRNA expression, ER stress responses, apoptosis‐linked transcripts, and remodeling‐associated transcripts, rather than as confirmed pathway inhibition or established antifibrotic activity. These data support juglone as a hepatoprotective candidate and identify protein‐level and functional validation as important next steps.
- Open Access
- 1 January 2024
- Published by Wiley in International Journal of Endocrinology
- Vol. 2024 (1) , 3914332
Viscosol Treatment Ameliorates Insulin‐Mediated Regulation of Dyslipidemia, Hepatic Steatosis, and Lipid Metabolism by Targeting PTP1B in Type‐2 Diabetic Mice Model
Type 2 diabetes mellitus (T2DM), a metabolic disorder, has the hallmarks of persistent hyperglycemia, insulin resistance, and dyslipidemia. Protein‐tyrosine phosphatase 1B (PTP1B) was found to be overexpressed in many tissues in the case of T2DM and involved in the negative regulation of insulin signaling. So, PTP1B inhibition can act as a therapeutic target for T2DM. Numerous studies claimed the anti‐inflammatory, hypoglycemic, hepatoprotective, and hypolipidemic activities of Dodonaea viscosa. Previously, we generated the high‐fat diet (HFD)‐low dose streptozotocin (STZ)–induced diabetic male mice model and treated it with a PTP1B inhibitor (5, 7‐dihydroxy‐3, 6‐dimethoxy‐2‐ (4‐methoxy‐3‐ (3‐methyl‐2‐enyl) phenyl)‐4H‐chromen‐4‐one), isolated from Dodonaea viscosa. In the current study, we aimed to investigate the De novo lipogenesis, adipocyte differentiation, augmentation of lipoproteins clearance, fatty acid uptake, antilipolysis activity, and hepatic steatosis of PTP1B inhibition in adipose and liver tissues of the HFD‐STZ–induced diabetic mice model. We found the retrieval of normal morphology of adipocytes and hepatocytes in the compound‐treated group. The biochemical parameters showed the gradual reduction of LDL, VLDL, TC, and TG in the serum of the compound‐treated group. To further test our hypothesis, real‐time PCR was performed, and data revealed the reduction of PTP1B and other inflammatory markers in both tissues, showing enhanced expression of insulin signaling markers (INSR, IRS1, IRS2, and PI3K). Our compound upregulated the adipogenic (PPARγ), lipogenic (SREBP1c, FAS, ACC, and DGAT2), lipoprotein clearance (LPL, LDLR, and VLDLR), fatty acid uptake (CD36 and FATP1), and lipid droplet forming (FSP27 and perilipin‐1) markers expressions in adipocytes and downregulated in hepatocytes. Furthermore, we found elevated cholesterol efflux (in adipose and liver) and decreased lipolysis in adipocytes and elevated in hepatocytes. Hence, we can conclude that our compound protects the adipocytes from abrupt lipolysis and stimulates adipocyte differentiation. In addition, it plays a hepatic protective role by shifting clearance and uptake of lipoproteins and fatty acids to the peripheral tissues and retrieving the fatty liver condition.
- 1 January 2024
- Published by Wiley in International Journal of Endocrinology
- Vol. 2024 (1) , 3914332
Open AccessViscosol Treatment Ameliorates Insulin‐Mediated Regulation of Dyslipidemia, Hepatic Steatosis, and Lipid Metabolism by Targeting PTP1B in Type‐2 Diabetic Mice Model
Type 2 diabetes mellitus (T2DM), a metabolic disorder, has the hallmarks of persistent hyperglycemia, insulin resistance, and dyslipidemia. Protein‐tyrosine phosphatase 1B (PTP1B) was found to be overexpressed in many tissues in the case of T2DM and involved in the negative regulation of insulin signaling. So, PTP1B inhibition can act as a therapeutic target for T2DM. Numerous studies claimed the anti‐inflammatory, hypoglycemic, hepatoprotective, and hypolipidemic activities of Dodonaea viscosa. Previously, we generated the high‐fat diet (HFD)‐low dose streptozotocin (STZ)–induced diabetic male mice model and treated it with a PTP1B inhibitor (5, 7‐dihydroxy‐3, 6‐dimethoxy‐2‐ (4‐methoxy‐3‐ (3‐methyl‐2‐enyl) phenyl)‐4H‐chromen‐4‐one), isolated from Dodonaea viscosa. In the current study, we aimed to investigate the De novo lipogenesis, adipocyte differentiation, augmentation of lipoproteins clearance, fatty acid uptake, antilipolysis activity, and hepatic steatosis of PTP1B inhibition in adipose and liver tissues of the HFD‐STZ–induced diabetic mice model. We found the retrieval of normal morphology of adipocytes and hepatocytes in the compound‐treated group. The biochemical parameters showed the gradual reduction of LDL, VLDL, TC, and TG in the serum of the compound‐treated group. To further test our hypothesis, real‐time PCR was performed, and data revealed the reduction of PTP1B and other inflammatory markers in both tissues, showing enhanced expression of insulin signaling markers (INSR, IRS1, IRS2, and PI3K). Our compound upregulated the adipogenic (PPARγ), lipogenic (SREBP1c, FAS, ACC, and DGAT2), lipoprotein clearance (LPL, LDLR, and VLDLR), fatty acid uptake (CD36 and FATP1), and lipid droplet forming (FSP27 and perilipin‐1) markers expressions in adipocytes and downregulated in hepatocytes. Furthermore, we found elevated cholesterol efflux (in adipose and liver) and decreased lipolysis in adipocytes and elevated in hepatocytes. Hence, we can conclude that our compound protects the adipocytes from abrupt lipolysis and stimulates adipocyte differentiation. In addition, it plays a hepatic protective role by shifting clearance and uptake of lipoproteins and fatty acids to the peripheral tissues and retrieving the fatty liver condition.